National Association for Proton Therapy launches physician advisory committee
National Association for Proton Therapy created a physician advisory committee to provide advice on topics such as clinical research, patient education and insurance reimbursement.
J. Isabelle Choi, MD, clinical director and research director of New York Proton Center and assistant member at Memorial Sloan Kettering Cancer Center, will serve as committee chair.
“We are excited that Dr. Choi will be chairing the physician advisory committee,” Jennifer Maggiore, the association’s executive director, said in a press release. “Dr. Choi’s efforts to advance proton therapy research and improve outcomes for [patients with cancer] makes her a terrific leader in this new role.”
Other committee members are Gopal Bajaj, MD, of Inova Schar Cancer Institute Proton Therapy Center; Brian Baumann, MD, of S. Lee Kling Center for Proton Therapy at Siteman Cancer Center at Washington University in St. Louis; Jeff Bradley, MD, of Emory Proton Therapy Center; Andrew Chang, MD, of California Protons Cancer Therapy Center; Steve Frank, MD, of MD Anderson Proton Therapy Center; James Gray, MD, of Provision CARES Proton Therapy Center; Brandon Gunn, MD, of MD Anderson Proton Therapy Center; Nancy Mendenhall, MD, of University of Florida Health Proton Therapy Institute; Minesh Mehta, MD, of Miami Cancer Institute Proton Therapy Center at Baptist Health South Florida; Charles Simone, MD, of New York Proton Center; Christina Tsien, MD, of The Johns Hopkins National Proton Center; Torunn Yock, MD, of Francis Burr Proton Therapy Center at Massachusetts General Hospital; and Jing Zeng, MD, of Seattle Cancer Care Alliance Proton Therapy Center.
Committee members will help promote the benefits of proton therapy, attend advocacy meetings with representatives of state and federal agencies and federal lawmakers, and support proton therapy research.
“I’m pleased to lead these expert proton therapy physicians who can help the organization expand insurance coverage guidelines, develop clinical trials, and promote the collaboration of proton therapy disease-specific research summaries for patients and those supporting access to proton therapy,” Choi said in the release.